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Heparin and heparinoids prevent the binding of immune complexes 
containing nucleosomal antigens to the GBM and delay nephritis in 
MRIJlpr mice. Monoclonal anti-nucleosome antibodies (mAbs) com- 
plexed to nucleosomal antigens can bind to DNA and to heparan sulfate 
(FIS) in ELISA and to the GBM in vivo in a rat renal perfusion system, 
whereas non-complexed mAbs do not bind [!]. In this study, we analyzed 
whether heparin (HEP) or N-desulfatcd/acetylated heparins (DSA-HEP), 
structurally and functionally strongly related to HS, are able to prevent the 
binding of these complexed mAbs to DNA and to HS in vitro and to rat 
GBM in vivo. In ELISA the binding of nucleosome complexed anti- 
nucleosome antibodies to DNA and IiS was inhibited dose-dependently 
by HEP, DSA-HEP and low molecular weight (LMW) DSA-HEP. 
Intravenous injection of nueleosome/anti-nucleosome immune complexes 
without heparin/heparinoids in BALB/c mice led to GBM binding, while 
simultaneous injection of heparin/heparinoids with complexed antibodies 
or pretreatment with heparin subcutaneously prior to injection of com­
plexes prevented this binding. Subsequently, we tested the preventive 
effect of HEP, DSA-HEP and LMW-DSA-HEP on progression of renal 
disease in MRL/Ipr mice. Treatment was started at an age of eight weeks 
in a dose of 50 ¡±g daily. With all three drugs albuminuria was significantly 
delayed compared to PBS treated controls (cumulative incidence of 
proteinuria at 20 weeks in controls 60% vs. 13%, 14% and 6% respectively 
for HEP, DSA-HEP and LMW-DSA-HEP; P <  0.05). At week 21 the 
glomerulonephritis was histologically less severe in heparin/heparinoid 
treated animals (P = 0.02). In immunofluorescence the amount of 
immunoglobulin and C3 deposits in the glomerular capillary wall tended 
to be less in heparin/heparinoid treated mice compared to PBS treated 
controls (P = 0.07). Furthermore, at 20 weeks anti-HS levels in plasma of 
heparin/heparinoid treated mice were significantly lower (P <  0.05). We 
conclude that interaction of heparin or heparin analogs with HS reactive 
immune complexes containing nucleosomal antigens prevents the binding 
of these immune complexes to the GBM and delays nephritis in MRLUpr 
mice.
Systemic lupus erythematosis (SLE) is an autoimmune disease 
characterized by the occurrence of numerous autoantibodies, 
primarily directed against nuclear antigens. Previously we have
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shown that these anti-nuclear antibodies complexed to nucleoso­
mal antigens are able to bind to the glomerular basement 
membrane (GBM) in vivo [1, 2]. In these nucleosome containing 
immune complexes the positively charged histones interact with 
the negatively charged HS in the GBM [1]. The presence of these 
nucleosomes in the complexes is also responsible for the binding 
to heparan sulfate (HS) and DNA in vitro, since non-complexed 
antibodies do not bind [1,3]. In the present study, we investigated 
whether heparin or heparin analogs, which have structurally and 
functionally strong similarities with HS, could interfere with the 
binding of these nucleosome complexed anti-nucleosome antibod­
ies to HS and DNA in vitro and to the GBM in vivo. Heparin is a 
drug with many biological activities [4] and the therapeutic effects 
of heparin in various experimental models of kidney diseases have 
been investigated. In the renal ablation model heparin reduced 
systemic blood pressure, proteinuria and the extent of glomerular 
sclerosis [5-8]. Also in lupus mice heparin reduced the glomerular 
damage [9]. In the puromycine aminonucleoside-induced n e ­
phrotic syndrome, heparin treatment prevented glomerular scle­
rosis, mesangial proliferation and reduction of the glomerular 
filtration rate [10]. The development of hypertension and fibrinoid 
vascular lesions was prevented by heparin treatment in spontane­
ously hypertensive rats [11, 12]. In most studies a similar protec­
tive effect was also found for non-anticoagulant heparinoids [7,
10], These results indicate that the beneficial effects can be 
obtained without the risks of anti-coagulation. Because of the 
renal protective properties and the functional and structural 
similarities with HS, we analyzed the effects of heparin (HEP) and 
the non-anticoagulant derivatives,
N-desulfa ted I a ce ty la ted heparin (DSA-HEP) and low molecular 
weight N-desulfated/acetylated heparin (LMW-DSA-HEP) on 
manifestations o f glomerulonephritis in a spontaneous model o f
SLE, the MRL/lpr mouse
We assessed the effects of heparin and of heparinoids on 
autoantibody formation, proteinuria and glomerular Ig and com­
plement deposition in MRL/lpr mice both prophylactically as well 
as therapeutically. In addition, we studied the effects of these
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drugs on the binding of complexed anti-nucleosomal autoantibod- 
ies in ELISA to DNA and HS, and in vivo to the GBM.
Methods
Animals
M RL IprHpr mice were bred from stock originally obtained via 
the Scripps Clinic and Research Foundation (La Jolla, CA, USA) 
from the Jackson Laboratory (Bar Harbor, ME, USA). All strains 
were maintained by brother/sister matings at our animal labora­
tory. For the in vivo inhibition studies, the in vivo coagulation 
studies and the in vivo assessment of immune modulation by the 
drugs, BALB/c mice were used, also originating from the Jackson 
Laboratory.
Dntgs
Heparin (HEP) was commercially obtained from Organon 
Technica BV (Boxtel, The Netherlands). As non-coagulant hep­
arin derivatives DSA-HEP (KF-E4282) and LMW-DSA-HEP 
(KF-E4567) were used, which were both produced and generously 
provided by Diosynth BV (Oss, The Netherlands). The N-desul- 
fation of heparin was carried out as described by Inoue and 
Nagasawa [13]. Briefly, heparin was dissolved in water and passed 
through a cation-column (Dowex SOW X 12) in the H +-form. The 
heparinic acid in the eluate was neutralized with pyridine (approx­
imately 2.5 ml per gram of heparin) to pH 6.5. After freeze-drying, 
the pyridine salt o f heparin was dissolved in 95% dimethylsul- 
phoxide and 5%  water and incubated for 30 minutes at 50°C. The 
desulfated heparin was obtained by adsorption on an anion 
exchanger (Bayer MP500A), elution with a 20% NaCl solution 
and precipitation with 75% methanol. Acetylation was carried out 
as described by ITirano and Ohashi [14]. The N-desulfated 
material was dissolved in a 10:1 water-methanol mixture and 1/20 
of the total volume of acetic anhydride (1 mi per gram of heparin) 
was added. The pH was kept constant by addition of a Dowex 1 X 
8 ion exchanger in the carbonate form. DSA-HEP was obtained 
by adsorption on an anion exchanger, elution, desalting on a G-10 
column and freeze drying. LMW-DSA-HEP was obtained by 
enzymatic (heparin lyase I, EC.4.2.2.7) digestion of HEP, which 
then was desulfated and acetylated as described above, The 
sulfate content was determined by conductometric titration as 
described by Casu and Gennaro [15], The N-acetyl content was 
determined by proton-NMR as described by Casu [16]. For 
control experiments a neutral polysaccharide Dextran (Pharma­
cia, Upsalla, Sweden) was used in concentrations identical to 
those of heparin/heparinoids.
Anticoagulation studies
The anticoagulant properties of DSA-HEP and LMW-DSA- 
H EP were analyzed and compared with standard H EP in vitro and 
in vivo. The assay for anti-factor Xa activity was carried out as 
described by Teien e t al [17, 18] with minor modifications for use 
in microtiter plates. In addition the effect of DSA-HEP, LMW- 
DSA-HEP or HEP on the activated partial thromboplastin time 
(aPTT) was determined by addition of the drugs to normal mouse 
plasma in a concentration range of respectively 0 to 50 and 0 to 10 
jiig/ml. For the in vivo effect groups of BALB/c and MRL/lpr mice 
were treated for three days with daily subcutaneous injections of 
0.1 ml saline or 50 pg  of either HEP, DSA-HEP or LMW-DSA- 
HEP. Two hours after the last injection 0.9 ml blood was obtained
by cardiac puncture in a 1 ml syringe containing 0.1 ml of CTAD 
solution (containing 0.089 m trisodium citrate, 0,021 m citic acid, 
15 ¡jlm  theophyllin, 3.7 p M  adenosine and 0.198 p M  dipyridamol). 
The plasma was collected after centrifugation and aPTT and 
heparin levels were determined, according to Fischer [19]. Briefly, 
in this assay 10 /¿I CTAD plasma or standard sample were mixed 
with 50 fxl normal pooled plasma as a source of antithrombin III 
and 150 p\ Tris-imidazole buffer (30 mM in 0.25 M NaCl, pH  8,4) 
and incubated for five minutes at 37°C. Thereafter 20 p\ thrombin 
(6 U/ml) were added and the mixture was incubated for exactly 30 
seconds. To measure the remaining free thrombin 20 p\ (2 mM) of 
the chromogenic substrate S 2238 (KabiVitrium) was added and 
two minutes later the reaction was stopped with 50 p\ 50% acetic 
acid. The extinction at 450 nm was measured in a E A R  400 
microplate reader (SLT, Grading, Austria). The heparin/AT 
Ill-complex mediated anti-thrombin activity (=  heparin level) was 
calculated from a standard curve obtained with heparin. T reat­
ment of BALB/c and MRL/lpr mice with HEP resulted in heparin 
levels of 6.0 ± 3.0 and 3.1 ±  1.5 mg/liter, respectively (controls 
0.3 ±  0.2 mg/1 iter). The aPTT was measured by mixing 100 p\ of 
citrated plasma with 100 pd P I T  reagent of Stago (Asnifcres, 
France) containing Kieselguractivator and cephalin. After incu­
bation for three minutes at 37°C, 100 p\ 25 mM CaCI2 was added 
and the clotting time was recorded with a KC 10 coagulometer 
(Amelung, Germany).
Preparation o f nucleosome complexed and purified
anti-nucleosome mAb
Anti-nucleosome antibodies are directed against nucleosome or 
subnucleosomal complexes consisting of the histone octamer and 
DNA. Purified non-complexed anti-nucleosome antibodies do not 
bind to individual histones or DNA. However, complexed to 
nucleosomal antigens these antibodies bind to DNA and HS in 
ELISA and to the GBM in vivo [1], Complexed antibodies of an 
anti-nucleosomal antibody, mAb #34, were obtained by purifica­
tion of culture supernatant under physiological conditions as 
described [1]. Noncomplexed mAb #34  was obtained by purifica­
tion under high salt conditions preceded by a DNase treatm ent as 
previously described [1],
Antigen reactivity o f purified and complexed anti-nucleosome mAb
and o f plasma samples
Anti-DNA and anti-HS reactivities were determined in ELISA 
as described previously [1, 20]. All ELISAs were titrated and the 
reciprocal of the dilution giving an absorption of 1,0 at 450 nm was 
used as titer.
Interaction o f heparin or heparinoids with complexed
anti-nucleosome mAh
The in vitro effects of heparin/heparinoids were analyzed in an 
inhibition ELISA to HS or DNA using a concentration range of 
heparin, heparinoids or dextran. Fifty microliters of the different 
inhibitors were added to the complexed anti-nucleosome mAb 
#34. After incubation for 45 minutes at room tem perature the 
reactivity of the mAb to HS or DNA was measured in ELISA as 
described before. In these inhibition experiments the mAb was 
used in a concentration that gave 50% of the maximal absorption 
in the respective direct ELISAs.
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The in vivo effects of heparin/heparinoids on GBM binding of 
complexed mAb #34  were evaluated in two different ways: (1) by 
renal perfusion studies in the rat o f complexed mAb #34 with or 
without heparin; (2) by i.v. injection in BALB/c mice of complexed 
mAb #34 with or without pretreatm ent of the mice with heparin. 
For the renal perfusion studies male Wistar rats (150 g) were 
anesthetized by intraperitoneal administration of 0.15 ml (9 mg) 
sodium pentobarbital (Narcovet; Appharma, Arnhem, the Neth­
erlands). The control renal perfusion was performed as described 
before [1], For inhibition experiments 150 ¡xg of complexed mAb 
#34 was mixed with 150 \xg of heparin/heparinoids for 30 minutes 
at room temperature before renal perfusion. After perfusion the 
perfused kidney was taken out and immediately snap frozen in 
liquid N2 for evaluation of IgG binding by immunofluorescence 
(IF).
The glomerular binding after i.v. injection of complcxed mAb 
was evaluated in BALB/c mice injected with 150 ¡xg complexed 
mAb #34  after pretreatm ent for three days with either daily 
subcutaneous injections of 0.1 ml PBS or 50 /xg HEP. Two hours 
after the last injection, the complexed mAb #34  was injected i.v. 
After five minutes the kidneys were taken out for IF.
Treatment protocols in M RL / lp r  mice
For the first set of experiments to test the preventive effect, 
eight-week-old MRL///;r mice were treated once daily with a 
subcutaneous (s.c.) injection of 50 ¡xg of either HEP, DSA-HEP 
or LMW-DSA-HEP in 0.1 ml PBS. Control animals received 0.1 
ml PBS s.c. daily. Each group consisted of 15 animals (8 males and 
7 females). Mice were treated from week 8 until week 21. At the 
start and after 12 weeks of treatm ent blood was drawn for the 
determination of the anti-DNA and anti-HS titer in plasma. 
Albuminuria was screened every week by urine collection in 
metabolic cages for 18 hours. After 13 weeks of treatment (at the 
age of 21 weeks) the animals were sacrificed and the kidneys were 
removed for immunofluorescence.
In a second set of experiments, the therapeutic effect on 
established albuminuria (albuminuria period before treatment <  
7 days) was assessed. MRL/lpr mice between the ages of 20 to 30 
weeks with an albuminuria of at least 1000 jug/18 hr were 
randomized for magnitude of albuminuria, age and sex to treat­
ment with either 50 /xg HEP, 50 fig LMW-DSA-HEP or 0.1 ml 
PBS once daily subcutaneously (each group M =  12). After the 
start of the treatment the albuminuria was analyzed every two 
weeks and the effect on survival was evaluated. At several time 
points during treatm ent plasma was collected for determination of 
anti-DNA and anti-HS titers.
To investigate whether treatm ent with heparinoids could form 
a useful addition to immunosuppressive treatment, we performed 
a pilot experiment in which we tested whether the combination of 
LMW-DSA-HEP and cyclophosphamide (CY) was more effective 
than CY treatment alone. MRL/lpr mice between the age of 20 to 
25 weeks with an albuminuria of at least 300 /xg/18 hr and a 
duration of albuminuria of less than seven days, were randomized 
for magnitude of albuminuria, age and sex. Mice were treated 
once daily s.c. with either PBS (group A  and group B) or with 50 
fig LMW-DSA-HEP (group C). In addition mice in groups B and 
C received a weekly i.p. injection of CY (EndoxanR-Asta; Dagra 
Pharma B.V., Diemen, The Netherlands) in a dose of 20 mg/kg 
body wt while control mice in group A received an equivalent 
volume of PBS. Each group consisted of 5 animals. The effect of
this treatment regimen was evaluated for albuminuria and sur­
vival.
Disease activity assessment
Anti-DNA and anti-HS reactivities were determined in ELISA 
as described above. The HS ELISA was used to detect nucleo­
some complexed autoantibodies in the circulation [3]. After 
collection of urine for 18 hours in metabolic cages, albuminuria 
was analyzed with radial immunodiffusion with rabbit anti-mouse 
albumin antibodies (Cappel, West Chester, PA, USA) as de­
scribed before [21,22]. Mouse albumin 5 mg/ml (Sigma Chemical 
Company, St. Louis, MO, USA) was used as a standard. To study 
the glomerular deposition of mouse Ig and C3 and staining of 
GBM HS, indirect immunofluorescence was performed on 2 ¡xm 
cryostat sections of kidney tissue, according to techniques de­
scribed previously [22]. The coded sections of the kidneys were 
analyzed by 3 different observers and scored semiquantitatively on 
a scale from 0 to 4+  (in at least 20 glomeruli per mouse kidney). 
For staining of Ig and C3 both the amount and intensity of 
staining was scored. No staining was scored 0; mild staining was 
scored 1; moderate staining was scored 3 and severe staining was 
scored 4. For HS staining in the capillary loops, no staining at all 
was scored 0, staining of 25% off all capillary loops and/or 75% 
decrease of staining intensity (as compared with a normal BALB/c 
glomerulus) was scored 1; staining of 50% off all capillary loops 
and/or 50% decrease of staining intensity was scored 2; staining of 
75% of all capillary loops and/or 25% decrease of staining 
intensity was scored 3, and normal staining of all capillary loops 
was scored 4. For light microscopy tissue fragments fixed in 
Bouin’s solution were dehydrated and embedded in Paraplast 
(Amstelstad B.V., Amsterdam, The Netherlands). Four-microme­
ter sections were stained with periodic acid-Schiff and silver 
methenamine [21]. Coded sections were analyzed and scored on a 
scale 0 to 3-h The 0 to 3+ scale was defined as follows: no 
glomerulonephritis was scored 0; mild/moderate glomerulone­
phritis was scored 1-f- to 2-f ; and severe glomerulonephritis was 
scored 2+  to 3+.
In vivo assessment o f immune modulating properties o f
heparin fheparinoids
The immunosuppressive properties of HEP, DSA-HEP and 
LMW-DSA-HEP were studied in normal BALB/c mice by mea­
suring their influence on delayed type hypersensitivity (DTH) and 
primary antibody response towards bovine serum albumin (BSA) 
according to methods described previously [23], In brief, DTH 
reactivity was determined in 4 groups of 10 BALB/c mice which 
were treated daily with 0.1 ml PBS s.c. or 50 \x% of either HEP, 
DSA-HEP or LMW-DSA-HEP. Treatment was started at day - 2 .  
At day 0 all mice received 0.1 mg BSA in 0.1 ml complete 
Freund’s adjuvant s.c. At day 13 a rechallenge was given of 5 /xl 
BSA s.c. (2 mg/ml) into the pinna of the right ear. As control 5 ¡x\ 
PBS was injected in the pinna of the left ear. At 4,24 and 48 hours 
after the rechallenge duplicate measurements of the ear thickness 
(X 10'~3) were made with an engineer’s micrometer. The DTH 
reactivity is expressed as the ratio between the swelling of the 
antigen injected site (R) and the saline injected site (L) as 
measured after 48 hours. At day 15 blood was collected from the 
same animals for the determination of the anti-BSA response. 
Anti-BSA titers were measured in ELISA 123]. During the whole
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Table 1* Biochemical characteristics and anti-coagulant properties of heparinoids and dextran used as a control non-chaiged polysacchaiidc
Drug Abbreviation
Number of 
sulfate groups 
per disaccharide
% Of glucosamine 
residues containing 
a N-acetyl group
Molecular
wt
Anti-Xa
activity
Uimg
aPTT
in vivo 
secM
Heparin HEP 3.0 25 15 kDa 200 39 ± 12
N-desuIfated/ acetylated heparin DSA-HEP 2.3 100 14 kDa <2.4 _ » 28 ± 8
Low molccular weight LMW-DSA-HEP 2.3 100 7 kDa <2,4 25 ± 5
N-desulfated/acetylated heparin 
Dextran Dextran 0 ND 14 kDa <2.4 ND
Values are given as means ± s d . The aPTT in PBS treated animals was 30 ± 6 sec. The values were statistically not different between drug and PBS 
treated animals.
a The aPTT in mice treated once daily with a subcutaneous injection of 50 fig of either HEP, DSA-HEP or LMW-DSA-HEP compared to mice 
treated with PBS (N = 5 per group)
400
■oc
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Fig. 1. Effect o f heparin (HEP; OJ, N-desulfatecUacetylated heparin (DSA- 
HEP; • )  or low molecular weight N-desulfatedlacetylated heparin (LMW- 
DSA-HEP; Q) on aPTT in vitro.
Inhibition o f the binding o f complexed anti-nucleosome m/ib to
HS or DNA by heparin or heparinoids in ELISA
In pure non-complexed form mAh 34 reacted only with nucleo- 
somes and had no reactivity with DNA or HS. Complexed with 
nucleosomcs, however, this mAb bound not only to nucleosomes 
but also to DNA and HS as described before [1]. The binding of 
complexed mAb #34 to HS and DNA could be inhibited by HEP, 
DSA-HEP and LMW-DSA-HEP in a dose-dependent manner as 
shown in Figure 2. More DSA-HEP and LMW-DSA-HEP were 
required to achieve a similar degree of inhibition as with heparin, 
which in all probability is due to the partial desulfation of the 
former reagents. In contrast to heparin and the heparinoids, 
dextran was not able to inhibit the binding of complexed mAb #34 
in these competitive inhibition ELISAs. This inhibition was not 
unique for mAb #34 since HEP, DSA-HEP and LMW-DSA-HEP 
could also inhibit to a similar degree the binding of other 
previously described [1] complexed anti-nucleosome mAbs (#2 
and #32) to HS and DNA (data not shown)
experimental period the daily administration of the drugs was 
continued.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney 
V-test. A two-sided P < 0.05 was considered to be statistically 
significant. Spearman’s correlation coefficient was used for linear 
regression analysis.
Results
Characteristics and anti-coagulant properties
The biochemical characteristics of HEP, DSA-HEP, LMW- 
DSA-HEP and dextran are listed in Table I. As can be seen only 
HEP had an anti-factor Xa activity in vitro while the other 
preparations were devoided of any anti-factor Xa activity. A 
similar pattern was observed analyzing the effect on the activated 
partial thromboplastin time (aPTT) in vitro, Even addition of 
large amounts of DSA-HEP and LMW-DSA-HEP gave hardly 
any prolongation of the aPTT (Fig. 1). To prolong the aPTT to
1.00 seconds 25 times more DSA-HEP than HEP was needed 
while addition of LMW-DSA-HEP had no effect. The effect on 
coagulation in vivo using 50 /xg of the various drugs is also shown 
in Table 1. In all drug treated animals the aPTT was not 
significantly different from control animals receiving PBS.
Inhibition o f glomerular binding o f complexed anti-nucleosome
mAb by heparin and heparinoids
Previously, we have shown that after renal perfusion of com­
plexed anti-nucleosome mAb #34 glomerular binding occurs, 
while in purified form the mAb does not show any binding [1]. In 
this study, we tested the effect of heparin/heparinoids on this 
GBM binding by renal perfusion (in Wistar rats) of complexed 
mAb #34 with or without heparin/heparinoids (N -  3 per group). 
When, prior to perfusion, complexed mAh #34 was mixed with 
PBS clear binding of the complex to the glomerulus was seen, 
After perfusion of complexed anti-nucleosome mAb #34 mixed 
with dextran a comparable binding was observed (Fig. 3A). 
However, the addition of heparin, DSA-HEP or LMW-DSA-HEP 
to the complexed mAb #34 could completely prevent the glomer­
ular binding (Fig. 3B). Similar results were obtained after pre­
treatment of BALB/c mice with either PBS or HEP. BALB/c mice 
were pretreated for three days with either daily s.c. injections of 
PBS or HEP (N  = 4 per group). Two hours after the last injection 
the complexed mAb #34 was injected i.v. Pretreatment of the 
mice with HEP resulted in detectable heparin levels (6.0 ±3 .0  
mg/liter; controls, 0.3 ± 0.2 mg/liter) in the plasma at the time of 
injection of the compexed anti-nucleosome mAb #34. When 
complexed mAb #34 was injected i.v. after pretreatment with a 
daily subcutaneous injection of PBS glomerular binding was 
observed identical to that shown in Figure 3A. In contrast to this,
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Fig. 2. inhibit ion o f  the binding o f  the complexed anti-nucleosome m/ib 
#34 to HS (A) and DNA (IJ) in the inhibition ELISA. Binding of complexed 
#34 was inhibited close dependency by HEP (O), DSA-HEP (□) and 
LMW-DSA-HEP (• ) .  Dextran (■) could not inhibit the binding. For 
abbreviations see legend Figure I.
i.v. injection of complexed mAb # 3 4  in heparin pretreated mice 
did not lead to any GBM binding.
Effects on glomerular disease in MRL/lpr mice
In the preventive study a daily dose 5Ü jug of IiEP, DSA-HEP 
or LMW-DSA-HEP significantly delayed the onset of albuminuria 
in MRL/lpr mice compared to PBS treated controls (P <  0.05; Fig. 
4). At 20 weeks the cumulative incidence of albuminuria in PBS 
treated animals was 60%, while in the drug treated groups this was 
respectively 13%, 14% and 6% for HEP, DSA-HEP and LMW- 
DSA-HEP. Furthermore, the administration of HEP or hepari­
noids prevented the development of the histological hallmarks of 
glomerulonephritis. At week 21, 10 out of 15 PBS treated control 
MRL/lpr mice had glomerulonephritis. In contrast, mice treated 
with HEP, DSA-HEP and LMW -DSA-HEP, respectively, showed 
a significant lower prevalence of glomerulonephritis (3/15, 3/14 
and 2/15 of the mice, respectively, P =  0.03, P ~  0.03, P — 0,008; 
Fisher Exact test; Fig. 5). In direct immunofluorescence of kidney
sections of drug-treated animals we found compared with PBS 
treated controls, that there was a decrease in the amount of 
immunoglobulin deposits in the glomerular capillary wall (P = 
0.07), but not in the mesangium (P = 0.90; Figs, 6 and 7 A, B). 
The pattern of C3 deposition along the glomerular capillary wall 
was identical to that of the Ig deposits. Less C3 deposits were 
observed in heparin/heparinoid treated groups (Fig. 7 C, D). 
Previously, we have shown that the staining of HS in the GBM of 
MRL/lpr mice is significantly decreased and correlated with the 
extent of IgG deposits [22]. In the present study we observed the 
same phenomenon, since HS staining was markedly decreased in 
the GBM of PBS treated mice compared with PBS treated 
controls. However, in heparin/heparinoid treated mice this de­
crease in HS staining was much less as compared to PBS treated 
controls (Fig. 7F). As we have described before [22] and also 
found in this study, there was an inverse correlation between HS 
staining and albuminuria (rs = -0,65, P <  0.0001) and GBM Ig 
deposits (rs = -0.54, P <  0.0001). At the start of the treatment 
the anti-DNA and anti-HS reactivities in plasma were similar in 
all groups and rose with age (data not shown). After 12 weeks of 
treatment the anti-HS levels were significantly lower in HEP, 
DSA-HEP or LMW-DSA-HEP treated groups (P <  0,05, 0.03 
and 0,05, respectively) compared to PBS treated controls (Fig. 8), 
At that time there were no dilferences in anti-DNA antibody 
levels between the groups. To establish whether HEP, DSA-HEP 
and LMW-DSA-HEP could also exert an antiproteinuric effect in 
MRL/lpr mice with an established albuminuria (range: 1000 to 
9000 ¿¿g/18 hr) animals were treated daily with 50 /xg HEP or 
LMW-DSA-HEP. In the PBS treated group there was an increase 
of albuminuria in 90% of the mice. HEP and LMW-DSA-HEP 
treated groups showed an increase of albuminuria in 55% and 
60% of the mice, respectively. This difference was not statistically 
significant. Both drugs also had no effect on survival, anti-DNA or 
anti-HS titers (data not shown).
In the pilot experiment, in which the additive effect of heparin 
to immunosuppressive treatment was tested, MRL/lpr mice with 
an established albuminuria were treated with PBS/CY or LMW- 
DSA-HEP/CY. Control mice were treated with PBS only. This 
experiment revealed that there was a significant beneficial effect 
on survival for the LMW-DSA-HEP/CY treated mice as com­
pared to PBS/CY treated mice (P <  0.05) and that the LMW- 
DSA-HEP/CY treatment halted the progression of the protein­
uria.
Effects on immune reactivity
Treatment with 50 ¡ig of either HEP, DSA-HEP or LMW- 
DSA-HEP had no effect on DTH reactivity or on the primary 
antibody response towards BSA (Table 2).
Discussion
This study shows that heparin and non-anticoagulant heparin 
derivatives are able to inhibit the binding of nucleosome com­
plexed antibodies to DNA and HS. Also the in vivo GBM binding 
of these complexes after renal perfusion was prevented. Further­
more, these drugs prevented the development of glomerular 
lesions in MRL/lpr mice. In addition, we found that heparin/ 
heparinoid treatment can retard the onset of albuminuria and 
significantly reduces anti-HS reactivity in plasma. Because hepa­
rin has many biological actions in inflammation and tissue repair 
this beneficial effect could be due to number of actions. It has
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Fig. 6. The amount o f fg deposition in glomerular capillaiy loops (H) and 
mesangium (Q) in glomeruli o f mice treated with PBS, HEP, DSA-HEP or 
LMW-DSA-HEP. Deposition of Ig in the mesangium is similar in all 
groups. A smaller amount of Ig deposition in the GBM was observed in 
heparin/heparinoid treated mice compared to PBS treated controls.
unaltered does not provide support for an immunosuppressive 
effect. Therefore, an alternative explanation for the renoprotec- 
tive effect seems more likely. Several years ago we found that 
anti-DNA antibodies could cross react with HS [3]. Later it 
became apparent that this binding was not a direct antibody 
binding but due to nucleosomes complexed to the antibody [2]. 
The histone part of the nucleosome was responsible for the 
binding to HS. Based on these in vitro results we could show that 
anti-nuclear antibodies complexed to nucleosomal antigens are 
potential nephritogenic immune complexes via their interaction 
with HS and other anionic sites in the GBM [1], These complexes 
can be identified in the circulation by using an anti-HS-ELISA [3]. 
This anti-HS reactivity correlates with the onset and exacerbation 
of renal manifestations of SLE [37-39]. In this study we show that 
heparin and heparinoids are able to prevent the binding of these 
complexed anti-nucleosome antibodies to DNA and HS in 
ELISA. In our view this inhibition is due to the binding of 
heparin/heparinoids to cationic charged nucleosomal antigens 
within the complex. This explanation is different from that offered 
by others showing inhibition of binding of SLE auto-antibodies to 
HS or DNA in ELISA by heparin [9, 40]. In these latter studies 
inhibition of “direct” binding was suggested. That inhibition of 
binding of nucleosome complexed anti-nuclear antibodies takes 
place also in vivo is suggested by our finding that the plasma 
anti-HS reactivity in the heparin/heparinoid treated mice was 
significantly reduced. The inhibitory effect of heparin/heparinoids 
is not restricted to serum-derived complexed autoantibodies but 
also to antibodies eluted from glomeruli in SLE nephritis. In 
glomerular eluates from albuminuric MRL//pr mice, besides 
strong anti-DNA reactivity, we also found anti-HS reactivity. Both 
reactivities could be inhibited by heparin and heparinoids (van 
Bruggen et al, unpublished observations). Similar results have 
been published not only for MRL//pr mice but also for human 
SLE nephritis [9], These data support the suggestion that the 
protective effect of heparin and heparinoids can be explained by 
their ability to prevent the binding of nucleosome containing 
immune complexes to HS in the GBM.
In line with the in vitro findings, we found in the acute GBM
binding studies that heparin/heparinoids were able to prevent 
GBM binding both after renal perfusion and after i.v. injection of 
nucleosome complexed antibodies. More importantly, a similar 
mechanism seems to occur in the chronic model of lupus nephritis 
in MRLjlpr mice. The onset of albuminuria was significantly 
postponed by heparin and the used heparinoids. This was also 
reflected by the decrease in histological severity of the glomeru­
lonephritis in the drug treated animals. Furthermore, the amount 
of immunoglobulin deposits in the glomerular capillary wall 
tended to be less in heparin/heparinoid treated MRL//pr mice 
compared to PBS treated controls. This decrease in IgG deposits 
is relevant for the degree of proteinuria, since we found a strong 
correlation between GBM-Ig deposits and albuminuria. Comple­
ment activation is an important contribution to tissue damage in 
diseases mediated by immune complexes like lupus nephritis. The 
pattern of C3 deposition along the capillary wall was identical to 
the Ig deposition. This suggests that the reduced deposition of C3 
in drug treated animals is secondary to the decrease of IgG 
deposition. However, we cannot exclude that heparin and the 
heparinoids had a direct effect on complement, since inhibition of 
complement activation in vitro and in vivo has been described [41,
42].
In this study we could confirm in the control group our earlier 
observation that in MRLflpr mice the staining of GBM-HS is 
strongly reduced and related to proteinuria and GBM-Ig deposi­
tion [22]. Heparin/heparinoids were able to prevent this decrease 
of HS staining significantly. As outlined above, this seems to be 
due to the reduction of deposition of nucleosome complexed 
autoantibodies in the GBM. A similar mechanism has been 
demonstrated for other cationic molecules like human platelet- 
derived cationic molecules [43] and platelet factor 4 [44], which 
binding to the glomerular polyanion was inhibited by heparin. 
However, in recent years data has emerged that points to addi­
tional mechanisms which could explain the observed beneficial 
effect of heparin. It was found that glycosaminoglycans (GAGs) 
like heparin could prevent the progressive loss of HS-associated 
anionic charges in the GBM in adriamycin nephropathy [45] and 
in streptozotocin-induced diabetic nephropathy [46, 47]. The 
significance of these observations is supported by our findings that 
GBM-HS expression in adriamycin nephropathy [48] and diabetic 
nephropathy [49] is significantly correlated to proteinuria. Indeed, 
in patients with insulin-dependent diabetes microalbuminuria was 
substantially reduced by heparin treatment [50], These protective 
effects were not related to the anticoagulant properties of the 
agents. It is therefore conceivable that exogenous administration 
of GAGs can interfere with the functional decrease of the 
glomerular polyanion, that is, HS. A similar mechanism might 
have contributed to the attenuation of the decreased expression of 
HS in the GBM by heparin/heparinoids as observed in this study. 
However, once albuminuria was established, heparin or heparin- 
oid treatment did not reduce it, suggesting that the loss of HS was 
not corrected anymore. We therefore assume that immune com­
plexes, once they are bound to the GBM, are not resolved by 
heparin/heparinoids.
Our preliminary data on the combination treatment of LMW- 
DSA-HEP and CY suggest that addition of non-anticoagulant 
heparinoids to immunosuppressive drugs in the initial phases of 
treatment of lupus nephritis could be of clinical importance. After 
initiation of the immunosuppressive treatment for disease flares 
the reduction of the autoantibody production is not immediate.
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Fig. 8. The anti-HS reactivity at the age o f 21 weeks in plasma samples of 
MRLilpr mice treated with PBS, HEP, DSA-HEP or LMW-DSA-HEP. 
Individual titers arc given plus the median value for each group. *P <  0.05.
Tabic 2. Influence of 50 fig daily of either HEP, DSA-HEP or LMW- 
DSA-HEP on delayed type hypersensitivity (DTH) and primary
antibody response after immunization with BSA
Treatment DTH R/L ratio“ Primary antibody response1
PBS 1.5 ± 0.2 100 (20-480)
HEP 1.4 ± 0.2 80 (40-320)
DSA-HEP 1.3 ± 0,1 280(10-640)
LMW-DSA-HEP 1.3 ± 0.2 320(10-1900)
Control animals were treated daily with PBS. Results are expressed as 
means ± sd  or medians (range). 
il ratio between the antigen (R) and PBS (L) injected site 
b titer
During this period, temporary treatment with heparinoids could 
prevent further glomerular damage by reducing the deposition of 
ncphritogenic complexes. Further studies are needed to see 
whether this promising option is realistic.
In conclusion, our study indicates that heparin, and more 
importantly non-coagulant heparin derivatives, are able to bind to 
nephritogenic complexes consisting of nucleosomes and anti- 
nuclear antibodies. This binding of heparin/heparinoids prevents 
the subsequent deposition of these nephritogenic immune com­
plexes in the GBM. By this diminution of IgG deposition the 
ensuing glomerular inflammation and albuminuria is reduced.
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